# Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

> **NCT03222167** · PHASE3 · UNKNOWN · sponsor: **Institute Of Cardiology & Internal Diseases, Kazakhstan** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Hepatitis C Genotype 1B
- Metabolic Syndrome
- Fibrosis, Liver
- Cirrhoses, Liver

## Interventions

- **DRUG:** Elbasvir/ Grazoprevir 50/100 mg fixed dose combination

## Key facts

- **NCT ID:** NCT03222167
- **Lead sponsor:** Institute Of Cardiology & Internal Diseases, Kazakhstan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10
- **Primary completion:** 2019-04
- **Final completion:** 2019-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03222167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03222167, "Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03222167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*